- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
Panelists examine the SUNLIGHT trial, which evaluated trifluridine/tipiracil (FTD/TPI) alone vs in combination with bevacizumab. The addition of bevacizumab demonstrated enhanced outcomes, supporting its role in extending survival while maintaining tolerability.
The rationale for combining bevacizumab with FTD/TPI lies in its complementary mechanisms, offering potential synergy that translates to improved patient benefit.
They also note that real-world experiences largely align with trial data, reinforcing clinical confidence in the regimen’s effectiveness across diverse patient populations.
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
October 9th 2025Surgeons are more likely to perform opportunistic salpingectomy when their peers have done so, underscoring the impact of physician networks in ovarian cancer prevention.
Read More
